リキッドバイオプシーの世界市場レポート 2025年

リキッドバイオプシーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR17.2％で27億6,000万米ドルに成長します。予測期間の成長は、アプリケーションの拡大、がんモニタリング、新興技術、コンパニオン診断、バイオマーカー探索に起因します。予測期間の主な動向には、がん検出とモニタリング、治療モニタリング、最小残存病変（mrd）モニタリング、がん以外のアプリケーションにおけるリキッドバイオプシーなどがあります。

がん検出の進歩に対する政府資金の増加は、リキッドバイオプシー市場の成長を促進する主な要因です。このような資金提供は、世界のがん負担の増加、治療成績向上のための早期発見の必要性、革新的な診断技術によるヘルスケアコスト削減の重視によるところが大きいです。政府の支援は、研究を加速し、臨床試験に資金を提供し、がんの早期発見と個別化治療アプローチのための先進的な非侵襲的診断法の使用を促進することにより、リキッドバイオプシーの開発を支援します。例えば、2024年10月、英国政府のウェブサイトであるgov.UKは、英国の研究・イノベーションに1億1,800万ポンド（1億5,038万米ドル）が割り当てられたと報告しています。したがって、がん検出の進歩に対する政府資金の増加がリキッドバイオプシー市場の成長を促進しています。

がん罹患率の上昇は、リキッドバイオプシー市場の拡大を促進すると予想されています。制御不能な細胞増殖と浸潤傾向を特徴とするがんは、リキッドバイオプシーの手法によって検出可能です。これらの技術は、患者の血液サンプル中の循環腫瘍DNA（ctDNA）や循環腫瘍細胞（CTC）のようながん特異的バイオマーカーを同定し、非侵襲的な診断とモニタリングを可能にします。例えば、米国がん協会（American Cancer Society Inc.）は、米国で新たにがんと診断される症例が、2022年の1,918,030例以上から、2023年には推定1,958,310例に増加すると予測しています。このようながん罹患率の急増は、リキッドバイオプシー市場の成長促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のリキッドバイオプシーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリキッドバイオプシー市場：成長率分析
• 世界のリキッドバイオプシー市場の実績：規模と成長、2019年～2024年
• 世界のリキッドバイオプシー市場の予測：規模と成長、2024年～2029年、2034年
• 世界のリキッドバイオプシー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリキッドバイオプシー市場：製品別、実績と予測、2019年～2024年、2024年～2029年、2034年
• アッセイキット
• 機器
• サービス
• 世界のリキッドバイオプシー市場：臨床応用別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 早期がん検診
• 治療法の選択
• 治療モニタリング
• 再発モニタリング整形外科
• 世界のリキッドバイオプシー市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• リファレンスラボ
• 病院と医師の検査室
• 学術研究センター
• 世界のリキッドバイオプシー市場、アッセイキットの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• cfDNAアッセイ
• ctDNAアッセイ
• エクソソームベースのアッセイ
• RNAベースのアッセイ
• タンパク質ベースのアッセイ
• 世界のリキッドバイオプシー市場、機器の種類別のサブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• PCR機器
• 次世代シーケンシング（NGS）機器
• マイクロアレイ機器
• 質量分析装置
• 世界のリキッドバイオプシー市場、サービスの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• テストサービス
• データ分析サービス
• ラボサービス
• カスタムアッセイ開発サービス

第7章 地域別・国別分析

• 世界のリキッドバイオプシー市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のリキッドバイオプシー市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リキッドバイオプシー市場：競合情勢
• リキッドバイオプシー市場：企業プロファイル
  • QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • Roche Diagnostics Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• Menarini Silicon Biosystems
• Biocept Inc.
• Janssen Diagnostics LLC
• Trovagene Inc.
• Fraunhofer-Gesellschaft
• MDX Health SA
• Agilent Technologies Inc.
• Illumina Inc.
• Oxford Nanopore Technologies Ltd.
• Quantum Biosystems Inc.
• Menarini Silicon Biosystems Inc.
• Pathway Genomics Corporation
• Sysmex Corporation
• Janssen Global Services LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リキッドバイオプシー市場2029年：新たな機会を提供する国
• リキッドバイオプシー市場2029年：新たな機会を提供するセグメント
• リキッドバイオプシー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A liquid biopsy is a non-invasive and relatively painless alternative to surgical biopsies, enabling healthcare professionals to obtain valuable information about tumors through a simple blood sample. It is a diagnostic test conducted on blood to identify the presence of cancerous cells, often used for early-stage cancer detection.

The primary product types within the liquid biopsy market encompass assay kits, instruments, and services. Assay kits provide the necessary reagents and components for conducting analytical tests, which are used in various industries such as food, cereals and dietary fiber, dairy, analytical laboratories, animal feed and nutrition, biofuels, biotechnology, wine, malting and brewing, and research. Liquid biopsy has numerous clinical applications, including early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, which are utilized by reference laboratories, hospitals and physician laboratories, and academic and research centers in the field of orthopedics and oncology, among others.

The liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides liquid biopsy market statistics, including liquid biopsy industry, regional shares, competitors with a liquid biopsy market share, detailed liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy industry. This liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liquid biopsy market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.46 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advances in cancer research, non-invasiveness, personalized medicine, regulatory approvals, early cancer detection.

The liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expanding applications, cancer monitoring, emerging technologies, companion diagnostics, biomarker discovery. Major trends in the forecast period include cancer detection and monitoring, therapeutic monitoring, minimal residual disease (mrd) monitoring, liquid biopsy in non-oncological applications.

The rise in government funding for cancer detection advancements is a major factor driving the growth of the liquid biopsy market. This funding is largely due to the increasing global cancer burden, the need for early detection to improve treatment outcomes, and the emphasis on reducing healthcare costs through innovative diagnostic technologies. Government support aids liquid biopsy development by accelerating research, funding clinical trials, and promoting the use of advanced, non-invasive diagnostic methods for early cancer detection and personalized treatment approaches. For example, in October 2024, gov.UK, a UK-based government website, reported that £118 million ($150.38 million) was allocated to UK Research and Innovation, including £54 million from the government and £64 million ($81.55 million) from partners. Therefore, the rise in government funding for cancer detection advancements is propelling the growth of the liquid biopsy market.

The rising incidence of cancer is expected to drive the expansion of the liquid biopsy market. Cancer, characterized by uncontrolled cell growth and invasive tendencies, is detectable through liquid biopsy methods. These techniques identify cancer-specific biomarkers like circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in a patient's blood sample, enabling non-invasive diagnosis and monitoring. For instance, the American Cancer Society Inc. projects an increase in newly diagnosed cancer cases in the USA, from over 1,918,030 cases in 2022 to an estimated 1,958,310 cases in 2023. This surge in cancer prevalence serves as a driver for the liquid biopsy market's growth.

Businesses are rapidly adapting to new market demands and are notably prioritizing the launch of cutting-edge products within the liquid biopsy sector. This initiative aims to address the ever-increasing requirement for liquid biopsy products and services, augmenting their revenue and establishing a competitive advantage over their competitors. As an example, in June 2023, Laboratory Corporation of America Holdings, a US-based healthcare company, introduced Labcorp Plasma Focus, a liquid biopsy test engineered for identifying cancer-associated biomarkers in individuals with advanced or metastatic solid tumors. The test leverages the analysis of cell-free DNA (cfDNA) present in a patient's blood sample, constructing a detailed genomic profile of their tumor. This approach equips oncologists to refine patient healthcare management by creating personalized and precisely targeted therapy strategies.

Prominent companies involved in the liquid biopsy market are dedicating their efforts to the development of extensive liquid biopsy panels to gain a competitive edge. These extensive liquid biopsy panels serve as advanced diagnostic tools, analyzing various biomarkers within a patient's blood sample to detect and monitor a wide array of diseases, notably cancer. For instance, in June 2022, Tempus Labs Inc., a US-based technology company focused on precision medicine through artificial intelligence, announced the introduction of xF+, the most expansive liquid biopsy panel clinically available. This panel covers a broader range of genes, including single nucleotide variants, indels in all genes, and an expanded coverage of translocations, gene rearrangements, and copy number variants. Additionally, the xF+ panel evaluates blood-based tumor mutational burden (bTMB) and microsatellite instability, providing essential predictive biomarkers for various cancer immunotherapies' efficacy.

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for $70 million. Through this acquisition, Veracyte aims to enhance its diagnostics platform by integrating whole-genome minimal residual disease (MRD) capabilities. This deal allows Veracyte to leverage C2i's AI-driven technology to improve the detection of circulating tumor DNA from blood samples, with the goal of expanding its cancer care offerings. C2i Genomics Inc., also based in the US, specializes in AI-powered liquid biopsy for cancer diagnostics.

Major companies operating in the liquid biopsy market include QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE PLC, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

North America was the largest region in the liquid biopsy market in 2024. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The liquid biopsy market includes revenues earned by entities by DNA collection tubes, tests, and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Assays Kits; Instruments; Services
• 2) By Clinical Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring Orthopedics
• 3) By End User: Reference Laboratories; Hospitals and Physician Laboratories; Academic and Research Centers
• Subsegments:
• 1) By Assays Kits: cfDNA Assays; ctDNA Assays; Exosome-based Assays; RNA-based Assays; Protein-based Assays
• 2) By Instruments: PCR Instruments; Next-Generation Sequencing (NGS) Instruments; Microarray Instruments; Mass Spectrometry Instruments
• 3) By Services: Testing Services; Data Analysis Services; Laboratory Services; Custom Assay Development Services
• Companies Mentioned: QIAGEN NV; Roche Diagnostics Ltd.; Bio-Rad Laboratories Inc.; Myriad Genetics Inc.; Guardant Health Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liquid Biopsy Market Characteristics

3. Liquid Biopsy Market Trends And Strategies

4. Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liquid Biopsy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liquid Biopsy Market Growth Rate Analysis
• 5.4. Global Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liquid Biopsy Total Addressable Market (TAM)

6. Liquid Biopsy Market Segmentation

• 6.1. Global Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Assays Kits
• Instruments
• Services
• 6.2. Global Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring Orthopedics
• 6.3. Global Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers
• 6.4. Global Liquid Biopsy Market, Sub-Segmentation Of Assays Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• cfDNA Assays
• ctDNA Assays
• Exosome-based Assays
• RNA-based Assays
• Protein-based Assays
• 6.5. Global Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCR Instruments
• Next-Generation Sequencing (NGS) Instruments
• Microarray Instruments
• Mass Spectrometry Instruments
• 6.6. Global Liquid Biopsy Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing Services
• Data Analysis Services
• Laboratory Services
• Custom Assay Development Services

7. Liquid Biopsy Market Regional And Country Analysis

• 7.1. Global Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liquid Biopsy Market

• 8.1. Asia-Pacific Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liquid Biopsy Market

• 9.1. China Liquid Biopsy Market Overview
• 9.2. China Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liquid Biopsy Market

• 10.1. India Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liquid Biopsy Market

• 11.1. Japan Liquid Biopsy Market Overview
• 11.2. Japan Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liquid Biopsy Market

• 12.1. Australia Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liquid Biopsy Market

• 13.1. Indonesia Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liquid Biopsy Market

• 14.1. South Korea Liquid Biopsy Market Overview
• 14.2. South Korea Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liquid Biopsy Market

• 15.1. Western Europe Liquid Biopsy Market Overview
• 15.2. Western Europe Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liquid Biopsy Market

• 16.1. UK Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liquid Biopsy Market

• 17.1. Germany Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liquid Biopsy Market

• 18.1. France Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liquid Biopsy Market

• 19.1. Italy Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liquid Biopsy Market

• 20.1. Spain Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liquid Biopsy Market

• 21.1. Eastern Europe Liquid Biopsy Market Overview
• 21.2. Eastern Europe Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liquid Biopsy Market

• 22.1. Russia Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liquid Biopsy Market

• 23.1. North America Liquid Biopsy Market Overview
• 23.2. North America Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liquid Biopsy Market

• 24.1. USA Liquid Biopsy Market Overview
• 24.2. USA Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liquid Biopsy Market

• 25.1. Canada Liquid Biopsy Market Overview
• 25.2. Canada Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liquid Biopsy Market

• 26.1. South America Liquid Biopsy Market Overview
• 26.2. South America Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liquid Biopsy Market

• 27.1. Brazil Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liquid Biopsy Market

• 28.1. Middle East Liquid Biopsy Market Overview
• 28.2. Middle East Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liquid Biopsy Market

• 29.1. Africa Liquid Biopsy Market Overview
• 29.2. Africa Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liquid Biopsy Market Competitive Landscape And Company Profiles

• 30.1. Liquid Biopsy Market Competitive Landscape
• 30.2. Liquid Biopsy Market Company Profiles
  • 30.2.1. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Diagnostics Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Liquid Biopsy Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. Menarini Silicon Biosystems
• 31.3. Biocept Inc.
• 31.4. Janssen Diagnostics LLC
• 31.5. Trovagene Inc.
• 31.6. Fraunhofer-Gesellschaft
• 31.7. MDX Health SA
• 31.8. Agilent Technologies Inc.
• 31.9. Illumina Inc.
• 31.10. Oxford Nanopore Technologies Ltd.
• 31.11. Quantum Biosystems Inc.
• 31.12. Menarini Silicon Biosystems Inc.
• 31.13. Pathway Genomics Corporation
• 31.14. Sysmex Corporation
• 31.15. Janssen Global Services LLC

32. Global Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liquid Biopsy Market

34. Recent Developments In The Liquid Biopsy Market

35. Liquid Biopsy Market High Potential Countries, Segments and Strategies

• 35.1 Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liquid Biopsy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer